📌 Key Takeaways
- Galderma’s Sculptra® (PLLA-SCA) received EU MDR certification for four body areas:
buttocks, posterior thighs, décolletage, and upper arms—announced at IMCAS 2026 in Paris. - A panel of 13 international experts published a consensus guidance
on injection protocols, dosing, and combination treatments for each body area. - Sculptra works fundamentally differently from HA fillers:
it stimulates the body’s own collagen production over weeks to months,
rather than providing immediate volume. - This EU approval does not automatically apply to other markets.
Patients should confirm regulatory status with their provider before treatment.
For decades, injectable aesthetics meant the face.
Nasolabial folds, cheek volume, perioral lines—
the conversation rarely extended below the chin.
That is beginning to change.
At the IMCAS 2026 World Congress in Paris (January 29–31, 2026),
Galderma announced that Sculptra® (poly-L-lactic acid, PLLA-SCA)
had received EU MDR (Medical Device Regulation) certification
for clinical use across four body areas:
the gluteal area, posterior thighs, décolletage, and upper arms.
This is not a marketing pivot.
It is a regulatory milestone backed by an international expert consensus—
and it reframes what “regenerative aesthetics” means in 2026.
INDEX
What Galderma Announced at IMCAS 2026
Sculptra® is a poly-L-lactic acid (PLLA-SCA) injectable manufactured by Galderma.
When injected, it triggers a controlled inflammatory response
that stimulates fibroblast activity, leading to collagen and ECM production—
a process known as biodermal remodeling.
Unlike HA fillers, results are not immediate.
The primary effect emerges over weeks to months as new collagen forms.
Sculptra has been used for facial rejuvenation globally for years;
the body indications announced in 2026 represent a significant expansion of its approved use.
Galderma made three distinct announcements at IMCAS 2026.
Announcement 1: EU MDR Certification — Four Body Areas Approved
Sculptra® received EU MDR certification for the following body indications:
- Gluteal area — improvement of cellulite appearance, lift, and skin firmness
- Posterior thighs — skin firmness and aesthetic improvement
- Décolletage — wrinkle reduction and skin texture improvement
(combination with Restylane Skinboosters recommended) - Upper arms — skin laxity and firmness improvement
Source: Galderma Press Release, January 22, 2026. galderma.com
Announcement 2: International Expert Consensus Guidance
A panel of 13 international specialists developed a consensus guidance
covering recommended injection volumes, anatomical targets,
and combination protocols for each of the four body areas.
Notably, for the décolletage, the consensus recommends combining Sculptra
with Restylane Skinboosters—
a biostimulator-plus-skinbooster protocol that reflects
one of the defining trends in regenerative aesthetics for 2026.
Source: Haddad A, et al. International consensus poster. IMCAS 2026; January 29–31, 2026; Paris, France.
Announcement 3: Scientific Presentations on PLLA-SCA Regenerative Mechanisms
Fabi SG et al. presented data on the regenerative mechanisms of PLLA-SCA at IMCAS 2026.
Existing peer-reviewed literature documents the cascade:
fibroblast activation → collagen, elastin, and ECM synthesis → dermal remodeling.
Involvement in adipogenesis (healthy fat cell formation) has been noted in review literature,
though detailed poster data from IMCAS 2026 was not independently verified for this article.
Source: MDPI Cosmetics. 2026;13(3):103 (PLLA-SCA review);
Galderma IMCAS 2026 Scientific Presentations.
(gluteal area, posterior thighs, décolletage, upper arms)
(IMCAS 2026, January 2026, Paris)
Why “Body Regenerative Aesthetics” Is Gaining Momentum
The expansion of Sculptra’s indications reflects three converging shifts
in how patients and practitioners think about aesthetic medicine.
Rapid weight loss—increasingly common in the era of GLP-1 medications like Ozempic and Wegovy—
and natural aging both cause skin laxity and volume loss across the body.
These changes require solutions distinct from facial treatments.
Injectable biostimulators offer a non-surgical alternative
to procedures like body lifts or liposuction.
As facial rejuvenation becomes more accessible and effective,
patients increasingly notice a disconnect between a refreshed face
and an aging body.
The demand for whole-body aesthetic coherence
is expanding the clinical scope of injectable treatments.
Massage, topical agents, and suction-based devices
have historically shown limited long-term efficacy for cellulite.
Biostimulators address the underlying tissue architecture—
dermal remodeling at the structural level—
which is a fundamentally different mechanism.
Biostimulators vs. HA Fillers: Understanding the Core Difference
Sculptra is frequently mischaracterized as a filler.
It is not.
The distinction matters clinically and in terms of patient expectations.
According to IAPAM’s June 2026 aesthetic medicine update,
the recommended sequencing approach is:
“Place the biostimulator first. Allow the collagen response to develop.
Then supplement with HA filler as needed.”
In practice: Sculptra first, HA filler second—
a sequencing principle that is becoming standard in 2026 protocols.
Regulatory Status by Market: What Patients Need to Know
The EU MDR certification announced at IMCAS 2026 applies to the European Union.
Regulatory approval in other markets—including the United States (FDA),
the United Kingdom (MHRA), Japan (PMDA), and others—
is governed by separate processes and timelines.
Patients outside the EU should confirm with their provider
whether body-area use of Sculptra is approved, cleared,
or constitutes off-label use in their jurisdiction.
Three questions worth asking at any consultation:
- ① “Is this body indication approved by the relevant regulatory authority in this country,
or is this off-label use?” - ② “How many sessions are planned, at what intervals,
and how will we assess results over time?”
(Given the delayed onset, a structured follow-up plan is essential.) - ③ “Will HA fillers or skinboosters be combined,
and at what point in the sequence?”
The concept of “face-body harmony” is clinically sound.
The question of what to do when the face looks younger
but the body hasn’t caught up
is one practitioners are hearing more often—
and it’s a legitimate clinical problem, not just a marketing angle.
Scultpra’s body indication expansion is one regulatory-backed answer to that question.
That said, EU approval and approval in your home market are two different things.
An MDR certification in Europe does not mean the same indication
has been cleared by the FDA, PMDA, or any other authority.
Before pursuing any treatment based on this news,
ask your provider exactly what regulatory basis
covers the specific use being proposed.
Summary
- Sculptra® (PLLA-SCA) received EU MDR certification for four body areas:
gluteal area, posterior thighs, décolletage, and upper arms.
The announcement was made at IMCAS 2026 (January 29–31, Paris)
alongside a consensus from 13 international experts. - The clinical targets are cellulite appearance, skin firmness, lift,
and long-term tissue remodeling—
fundamentally different from HA fillers,
which provide immediate volume through direct injection. - The expansion reflects broader trends:
post-GLP-1 body changes, the face-body harmony aesthetic shift,
and the structural limitations of conventional cellulite treatments. - EU MDR approval does not extend automatically to other markets.
Patients should verify regulatory status, treatment sequencing,
and combination protocols with their provider before proceeding.
“Is this body indication approved by the regulatory authority in this country,
or is this off-label use?”
EU approval and local market approval are not the same thing.
How a clinic answers this question reveals a great deal about its transparency.
Frequently Asked Questions
and whether topical or local anesthesia is used.
For facial injections, topical anesthetic cream is standard.
Post-treatment swelling, bruising, and nodularity can persist for 1–2 weeks.
Body injections typically require larger volumes,
which may result in longer downtime than facial treatments.
A thorough pre-treatment consultation with your provider is essential.
Sculptra (PLLA) has no immediate volumizing effect;
results develop over 2–3 months as collagen is produced.
Radiesse (CaHA) provides both immediate volume
and longer-term collagen stimulation.
For body firmness and cellulite improvement,
Sculptra now has EU MDR approval for four specific areas.
Radiesse also has body use precedent.
Which is appropriate depends on the area, goal, and individual skin condition—
a decision best made with a qualified practitioner.
fibrous septae contraction, fat lobule protrusion, and impaired microcirculation.
Biostimulators like PLLA and CaHA target dermal and subdermal tissue remodeling,
improving skin firmness and surface uniformity—
which can reduce the visible appearance of cellulite.
The realistic goal is improvement in appearance, not complete elimination.
Individual results vary considerably,
and expectation-setting with your provider before treatment is important.
Sources
1. Galderma. “IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio.” Press Release. January 22, 2026. galderma.com
2. Haddad A, et al. International consensus: Sculptra®/Restylane® Skinboosters™ for non-facial rejuvenation. Poster presented at IMCAS 2026; January 29–31, 2026; Paris, France.
3. Fabi SG, et al. Regenerative aesthetic effects of poly L-lactic acid treatment. Poster presented at IMCAS 2026; January 29–31, 2026; Paris, France.
4. Sculptra®. EU Instructions for Use. 2025 (EU MDR certification, body indication details).
5. IAPAM. “June 2026 Aesthetic Medicine Update: Better Treatment Sequencing.” June 2026. iapam.com (Practitioner education content; not a formal clinical guideline.)
